Partial regimen replacement with aripiprazole reduces serum prolactin in patients with a long history of schizophrenia: a prospective open-label study

Partial regimen replacement with aripiprazole reduces serum prolactin in patients with a long history of schizophrenia: a prospective open-label study - Partial regimen replacement with aripiprazole reduces serum prolactin in patients with a long history of schizophrenia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1091220245

Enrollment

Registered

2016-03-08

Start date

2010-08-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia

Interventions

Intervention type:DRUG Name of intervention:before-after study Dose form / Japanese Medical Device Nomenclature:TABLET Route of administration / Site of application:ORAL Dose per administration:6-30 6

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria were a diagnosis of schizophrenia or a diagnosis in the range of schizophrenia (F2) according to the International Classification of Diseases, version 10 (ICD-10) by a psychiatrist.

Exclusion criteria

Exclusion criteria: Exclusion criteria were: 1) risk factors that could possibly influence prolactin level (e.g., patients with a prolactin-producing tumor or an endocrine disease such as thyroid disease, and pregnant or lactating female patients), 2) lack of study cooperation or unreliable data, and 3) factors that could possibly influence blood glucose level (e.g., patients with diabetes mellitus).

Design outcomes

Primary

Measure	Time frame
serum prolactin	—

Secondary

Measure	Time frame
Global Assessment of Functioning (GAF) , the Clinical Global Impression of Improvement (CGI-I) scale, body weight, and blood glucose level	—

Countries

Japan

Contacts

Public ContactKeiko Naono

Faculty of Medicine, University of Miyazaki

keiko_naono@med.miyazaki-u.ac.jp+81-985-85-2969

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026